05.08.2026

Opus Genetics Reports Vision Restoration Data Across Multiple Gene Therapy Programs

Key Takeaways Opus Genetics reported strong early clinical evidence that its OPGx-LCA5 gene therapy may restore cone-mediated daytime vision in children with severe inherited retinal disease, with improvements seen in visual acuity, light response, and daily functional vision Early data from the company’s OPGx-BEST1 program showed meaningful visual improvements and retinal structural gains in treated patients Preclinical findings from Opus Genetics’ RHO programs demonstrated preservation of retinal structure and function across animal models Opus Genetics unveiled new clinical and preclinical findings at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, highlighting advances in therapies aimed at restoring vision and preventing blindness. The company presented data from several programs, including OPGx-LCA5, OPGx-BEST1, and OPGx-RHO, providing evidence that gene therapy may be capable of restoring functional vision in patients with severe, early-onset retinal degeneration.